Company: GRCE
Filing Date: 2025-10-23
Form Type: 8-K
Source: 0001140361-25-039020
Chunk: 0

Company: Grace Therapeutics, Inc.
Filing Date: 2025-10-23
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01.      Other Events.  

On October 23, 2025, Grace Therapeutics, Inc. (the “ Company”)
issued a press release announcing that the Company has secured approximately $4.0 million in additional funding through exercises of common warrants that were previously issued in a private placement that the Company closed in September 2023. The remaining 1,190,927 common warrants issued in the 2023 private placement have expired as the
60th day after the U. S. Food and Drug Administration’s acceptance for review of the Company’s New Drug Application for GTx-104 has passed. GTx-104 is a clinical-stage, novel, injectable formulation of nimodipine being developed for I. V.
infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage patients.

A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference
into this Item 8.01.